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There are few studies comparing lesion evolution across different CNS demyelinating diseases,
yet knowledge of this may be important for diagnosis and understanding differences in disease
pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte gly-
coprotein immunoglobulin G (IgG)–associated disorder (MOGAD), aquaporin 4 IgG–positive
neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS).
Methods
In this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD,
AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6
weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two
neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion).
MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to de-
termine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined
acutely and at follow-up to assess variation in size.
Results
We included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks
(brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2–74]),
AQP4-IgG-NMOSD (53 [10–78]), and MS (37 [16–61]) (p < 0.01) and female sex pre-
dominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not
among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was
more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-
NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29
[0%]) (p < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18
[39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%])
and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) (p < 0.01). There was a larger median (range)
reduction in T2 lesion area in mm2 on follow-up axial brain MRI with MOGAD (213
[55–873]) than AQP4-IgG-NMOSD (104 [0.7–597]) (p = 0.02) and MS (36 [0–506]) (p <
0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0–888])
and AQP4-IgG-NMOSD (309 [0–1885]) were similar (p = 0.4) and greater than in MS (23
[0–152]) (p < 0.001).
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Discussion
TheMRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD andMS. This has implications for
diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS de-
myelinating diseases.
Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin
G (IgG)–associated disorders (MOGAD), aquaporin 4
(AQP4)–IgG–positive neuromyelitis optica spectrum disorder
(AQP4-IgG-NMOSD), and multiple sclerosis (MS) are distinct
inflammatory demyelinating disorders of the CNS.1-4 Despite
some overlapping manifestations, prior studies have highlighted
major differences among these disease entities, especially con-
cerning attack severity and clinical course.5-7 While AQP4-IgG-
NMOSD and MOGAD are characterized by severe attacks that
typically result in major acute disability (e.g., paraplegia, en-
cephalopathy, blindness) and are frequently accompanied by
largeMRI T2 lesions in the brain (>3 cm inmaximumdiameter)
or the spinal cord (≥3 contiguous vertebral body segments), MS
attacks are typically of milder clinical severity and accompanied
by smaller lesions on brain/spinal cord MRI, although tume-
factiveMS lesions occur in some patients.5,6,8-11 In the long term,
however, the course of these disorders does not generally reflect
the severity of the initial attacks: patients with MOGAD fre-
quently have better outcomes than those with AQP4-IgG-
NMOSD despite similarly severe attacks at nadir, while sec-
ondary progressive disability is essentially exclusive to MS de-
spite milder disease attacks in this condition.12-14 The exact
reasons for these clinical differences are unclear.
Most MRI studies in these 3 disorders have focused on attack
lesion location and morphology or global measures of atrophy,
while T2 lesion evolution has rarely been assessed.5,6,10,15-17
Studying the temporal evolution of different demyelinating lesions
onMRI after an initial attackmight improve our understanding of
differences in disease course, inform diagnosis, and help plan
optimal strategies for monitoring disease activity and treatment.
We investigated the temporal evolution of demyelinating lesions
onMRI after a single brain or spinal cord clinical attack in patients
with MOGAD, AQP4-IgG-NMOSD, and MS.
Methods
Standard Protocol Approvals, Registrations,
and Patient Consents
The study was approved by the institutional review board of
the Mayo Clinic. All patients consented to the use of their
medical records for research purposes.
Identification of Disease Cohorts
Three cohorts of patients were retrospectively identified:
(1) patients with MOGAD consecutively seen at Mayo
Clinic between January 1, 2004, and August 31, 2019 or (2)
AQP4-IgG-NMOSD consecutively seen at Mayo Clinic
between January 1, 2000, and August 31, 2019; and (3)
patients with MS or clinically isolated syndrome from both a
clinic-based cohort of patients consecutively seen by a
neurologist (E.P.F.) at the Mayo Clinic MS outpatient ser-
vice from January 1, 2015, to May 30, 2018, and a previously
identified population-based cohort (Olmsted County, MN)
of prevalent MS cases on December 31, 2011.8 Only patients
with the characteristic MOGAD, AQP4-IgG-NMOSD, or
MS clinical–MRI phenotypes were included as per published
international diagnostic criteria.18-20 A total of 19 patients
were previously reported.5,12,21
Inclusion and Exclusion Criteria
From these cohorts, our inclusion criteria required all of the
following: (1) first brain or myelitis attack; (2) available
acute brain/spinal cord MRI obtained within 6 weeks of the
attack nadir; and (3) available follow-up MRI beyond 6
months after the acute MRI. We excluded those with interval
relapses involving the same region as the initial attack (brain
or spine) to avoid overlap of MRI abnormalities that could
bias assessment of single T2 lesion evolution. Interval re-
lapses affecting different CNS regions were allowed (e.g.,
optic neuritis after an initial myelitis attack). When multiple
acute MRIs were available, the one showing the most ex-
tensive CNS abnormalities was chosen for analysis as this
was considered to be most representative of attack nadir. In
cases with multiple follow-up MRIs, the last MRI before a
relapse affecting the same CNS region of the initial attack (if
any) or last clinical follow-up was analyzed. In patients who
had concomitant brain and myelitis attack at the same time,
these were analyzed separately. Clinically isolated optic
neuritis attacks with or without MRI evidence of brain or
spinal cord asymptomatic involvement were not considered
brain attacks. Patients presenting with clinically isolated
optic neuritis were not included unless they had a sub-
sequent brain or myelitis attack, which was considered the
index attack for analysis.
Glossary
AQP4 = aquaporin 4; AQP4-IgG-NMOSD = aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum
disorder; EDSS = Expanded Disability Status Scale; FLAIR = fluid-attenuated inversion recovery; IgG = immunoglobulin G;
IVIg = IV immunoglobulin; MOG = myelin oligodendrocyte glycoprotein; MOGAD = myelin oligodendrocyte
glycoprotein–immunoglobulin G–associated disorder; MS = multiple sclerosis; PLEX = plasma exchange.
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Autoantibody Testing
Serum positivity for AQP4-IgG was determined by live (in-
house fluorescence-activated cell sorting assay) or fixed
HEK293 cells transfected with a plasmid encoding AQP4 (n =
49) or tissue immunofluorescence (n = 2).22 Serum positivity
for MOG-IgG1 was confirmed by a clinically validated flow
cytometry assay utilizing live full-length MOG-transfected
HEK293 cells.5 Samples analyzed included those tested at the
time of an acute attack and archived stored samples that were
re-analyzed.
Clinical Characteristics
Demographic, laboratory, and clinical data were abstracted
(E.S., M.B). Relapses were defined as neurologic disturbances
of at least 24 hours duration and occurring after a period of
remission of >1 month. Disability assessment was performed
at nadir of the initial attack and the closest clinical follow-up to
the analyzed follow-up MRI using the Expanded Disability
Status Scale score (EDSS).
Identification of Index Demyelinating Lesions
After medical records review, an index lesion was defined as an
acute lesion that was anatomically explanatory for the clinical
manifestations or, when multiple possible symptomatic acute le-
sions (e.g., multifocal brain T2 hyperintensities in a patient with
encephalopathy) were present, the largest was selected as the index
lesion. This index lesion was initially identified for each included
attack by 2 neurologists (E.S., E.P.F.) by consensus, and the neu-
roradiologists were advised of its location before imaging review.
MRI Determination of Lesion Evolution and
Lesion Size
All included acute and follow-up brain and spinal cord MRIs
were sorted in random order and independently reviewed by
2 neuroradiologists (S.M., K.N.K.) blinded to the diagnosis
and serology status. Lesion resolution or persistence on
follow-up MRI was determined, and consensus was reached
after discussion when disagreement occurred. To assess evo-
lution in T2 lesion size over time, a single neuroradiologist
Figure 1 Examples of Sagittal and Axial Area Measurements for Spinal Cord and Brain T2 Lesions
The left part of the figure shows sagittal (A.a, A.b, B.a) and axial (A.c, B.b) T2-weighted images of a longitudinally extensive spinal cord lesion associated with
aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD) acutely (A) and at follow-up (B). The largest acute axial
area of the lesionwasmanually outlined acutely on sagittal (A.b, yellow outline) and axial (A.d, yellow outline) images and at follow-up (B.c) to determine lesion
resolution/reduction. In the center of the figure, an acute brainstem T2-hyperintense lesion associated with myelin oligodendrocyte glycoprotein–
immunoglobulin G–associated disorder (MOGAD) is shown on axial fluid-attenuated inversion recovery images (C.a). The largest axial T2 lesion areamanually
outlined acutely (C.b, yellow outline) resolves to undetectable at follow-up MRI (D). On the right, a multiple sclerosis (MS) myelitis T2-hyperintense lesion is
shown (E.a, E.b) with the largest area of the T2-hyperintense lesion outlined acutely on both sagittal (E.b, yellow outline) and axial (E.d, yellow outline) images.
Despite being smaller acutely compared to the lesions associated with AQP4-IgG-NMOSD andMOGAD, the MS lesion only showsmoderate reduction in size
at follow-up, where it is still clearly visible on both sagittal (F.a, yellow outline) and axial (F.b, F.c, yellow outline) images.
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(K.N.K or S.A.M.) manually measured the largest axial area
(mm2) of the index brain and spinal cord lesions, and largest
sagittal area and longest lesion length in contiguous vertebral
body segments (0.5 ormore) for the spinal cord lesions only, in
the acute and follow-up MRIs (Figure 1). When inspecting the
index lesion location on follow-up MRI examination, the sec-
ond examination was displayed side-by-side with the index
examination and lesion location was coregistered visually prior
to characterization andmeasurement. Images were obtained on
a variety of different scanners from both outside centers and
Mayo Clinic and were analyzed by using QREADS Clinical
Image Viewer 5.10.8. Additional MRI parameters collected
included (1) frequency of patients with >15 T2-hyperintense
lesions on T2/fluid-attenuated inversion recovery (FLAIR)
images; (2) number of infratentorial T2 lesions on T2/FLAIR
images; (3) number of spinal cord T2-hyperintense lesions on
T2-weighted images; (4) presence of abnormally enhancing
lesions on postgadolinium T1-weighted images acutely and at
follow-up; and (5) presence of residual lesional T1 hypo-
intensity in the brain or spinal cord parenchyma at follow-up.
Statistical Analysis
Continuous and categorical variables were reported as median
(range) and number (%), respectively. Comparisons across
the 3 groups were performed by using the Kruskal-Wallis test
for continuous variables and Fisher exact test for categorical
variables. Pairwise comparisons were performed by using the
Wilcoxon rank sum test for continuous variables and Fisher
exact test for categorical variables. Potential associations were
explored by univariate logistic regression. A p value <0.05 was
considered statistically significant (JMP Pro 14.1.0). Graphs
were created with Microsoft Power Point 2010.
Data Availability
Anonymized data used for this study are available upon rea-
sonable request from the corresponding author.
Results
A total of 156 patients were included (MOGAD, 38; AQP4-
IgG-NMOSD, 51; MS, 67) with a total of 172 attacks (brain,
81; myelitis, 91). In 16 patients (MOGAD, 8; AQP4-IgG-
NMOSD, 4; MS, 4) both a brain and a myelitis attack were
analyzed, which occurred within the same month in 14. Their
demographics, laboratory, and clinical characteristics are sum-
marized in Table 1. In theMS cohort, the clinical phenotypes at
last follow-up were as follows: relapsing-remitting MS, n = 63;
single attack progressive MS, n = 2; and clinically isolated
syndrome, n = 2. Among AQP4-IgG-NMOSD and MOGAD,
no patient had developed a progressive course at last follow-up.
All patients with MOGAD tested negative for AQP4-IgG,
while in the AQP4-IgG-NMOSD cohort, 38 of 51 (75%) were
tested for MOG-IgG, uniformly with negative results. In the
MS cohort, 36 (54%) and 31 (46%) of 67 were tested for
AQP4-IgG and MOG-IgG, respectively, all of whom were
seronegative, including the 2 patients with clinically isolated
syndrome who tested negative for both antibodies.
Description of the Attacks
The brain symptoms accompanying the index lesions were
encephalopathy or focal symptoms attributable to supra-
tentorial brain regions in 12 (MOGAD, 7; AQP4-IgG-
NMOSD, 0; MS, 5; p = 0.003), brainstem/cerebellar syn-
drome in 56 (MOGAD, 10; AQP4-IgG-NMOSD, 18; MS,
28; p = 0.1), and combinations thereof in 13 (MOGAD, 1;
AQP4-IgG-NMOSD, 3; MS, 9; p = 0.4). In patients with an
initial myelitis attack, spinal cord MRI demonstrated cervical
involvement in 31 (MOGAD, 6; AQP4-IgG-NMOSD, 9;
MS, 16; p = 0.02), thoracic involvement in 21 (MOGAD, 7;
AQP4-IgG-NMOSD, 11; MS, 3; p = 0.1), or involvement of
both regions in 39 (MOGAD, 15; AQP4-IgG-NMOSD, 14;
MS, 10; p = 0.36). In patients with MOGAD, the included
attacks occurred as part of an acute disseminated encepha-
lomyelitis or with MRI evidence of multifocal CNS in-
volvement without encephalopathy in 22/38 (58%) or as
isolated brain (4/38 [11%]) or myelitis (12/38 [32%]) at-
tacks with or without concomitant optic neuritis.
Interval Treatment
Acute immunotherapy (within 6 weeks from the index attack
nadir) was more commonly a monotherapy of IV or oral
corticosteroids in the MS cohort (43/46 [93%]) compared to
the MOGAD (23/38 [61%]) and AQP4-IgG-NMOSD (29/
46 [63%]) groups (p < 0.001), although single-agent treat-
ments with IV immunoglobulins (IVIg; 2 patients with
MOGAD) or plasma exchange (PLEX; 1 patient with AQP4-
IgG-NMOSD) were also administered. In addition to corti-
costeroids, 1 or more adjunctive acute treatments utilized in
each disorder included the following: MS (PLEX, 3); AQP4-
IgG-NMOSD (PLEX, 16; IVIg, 2); and MOGAD (PLEX, 7;
IVIg, 6). After the acute phase, most of the patients in the 3
groups received different maintenance immunomodulating or
immunosuppressive agents, as detailed in Table 1.
Other CNS Interval Relapses
Relapses in other regions of the nervous system were allowed
between the attack MRI and the follow-up MRI. This in-
cluded myelitis interval relapses in patients with initial brain
attacks in 8/21 (38%) patients with AQP4-IgG-NMOSD, 9/
18 (50%) patients with MOGAD, and 16/42 (38%) patients
with MS (p = 0.83), and interval brain or optic neuritis re-
lapses in patients with initial myelitis attacks in 10/34 (29%)
patients with AQP4-IgG-NMOSD, 13/28 (46%) patients
with MOGAD, and 5/29 (17%) patients with MS (p = 0.07).
MRI Lesion Evolution
The acute and follow-up MRI characteristics for the included
attacks are summarized and compared in Tables 2 and 3;
representative examples of brain and spinal cord MRI lesion
evolution are shown in Figures 1–3. Graphs of the main dif-
ferences in MRI lesion evolution measures for the 3 disease
groups are included in Figure 4. In patients with brain attacks,
the median (range) number of total available follow-up brain
MRIs per patient before a brain relapse or last clinical contact
was 3 (1–14): AQP4-IgG-NMOSD, 3 (1–10); MOGAD, 3
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(1–13); MS, 3.5 (1–14). In patients with myelitis attacks, the
median (range) number of available follow-up spinal cord
MRIs per patient before a myelitis relapse or last clinical
contact was 2 (1–8): AQP4-IgG-NMOSD, 2 (1–7);
MOGAD, 3 (1–7); MS, 2 (1–8).
Index T2 Lesion Resolution
Complete resolution of the brain index lesion, with or without
normalization of the entire brain MRI, was observed in 72% of
patients with MOGAD, 17% of patients with MS, and 14% of
patients with AQP4-IgG-NMOSD (p < 0.001) (Table 2). In the
AQP4-IgG-NMOSD and MS groups, all index lesions that re-
solved completely were infratentorial, while in the MOGAD
group, they were both supratentorial (n = 6) and infratentorial
(n = 7).
Complete resolution of the myelitis index lesion was observed
in 79% of patients with MOGAD, 0% of patients with MS,
and 0% of patients with AQP4-IgG-NMOSD (p < 0.001)
(Table 3). In patients with a myelitis attack, resolution of the








Patients 51 38 67 — — —
Age at initial attack, y, mean (range) 53 (10–78) 25 (2–74) 37 (16–61) <0.0001 0.002 <0.0001
Pediatric (age <18 y) 2/51 (4) 14/38 (37) 2/67 (3) 0.0001 <0.0001 1.0
Female sex 41/51 (80) 17/38 (45) 51/67 (76) 0.001 0.002 0.7
CSF OCB (≥2) 4/25 (16) 3/23 (13) 31/36 (86) 1.0 <0.0001 <0.0001
Total number of attacks 55 46 71 — — —
Brain attacks 21 18 42 — — —
Myelitis attacks 34 28 29 — — —
Initial attack as disease presentationa 30/51 (59) 31/38 (82) 41/67 (61) 0.04 0.05 0.9
Median EDSS at attack nadir (range) 6 (2–9.5) 6 (3–9) 3 (0–7) 0.7 <0.0001 <0.0001
Acute treatment 46/50 (92) 38/38 (100) 46/67 (69) 0.3 <0.0001 0.001
Corticosteroids 45 36 46 — — —
PLEX 17 7 3 — — —
IVIg 2 8 0 — — —
Maintenance therapy 47/51 (92) 30/38 (79) 51/67 (76) 0.1 0.8 0.03
Corticosteroids 32 23 9 — — —
MMF, AZA 32 13 1 — — —
Anti-CD20b 21 7 3 — — —
IFN-β, GA 2 4 38 — — —
DMF, FGD, NTZ, TER 1 1 25 — — —
Other 12 4 2 — — —
Median EDSS score at last follow-up (range) 3 (0–8) 1 (0–7) 1 (0–7) <0.0001 0.5 <0.0001
Median EDSS score ≥6 at last follow-up 10/49 (20) 2/38 (5) 4/65 (6) 0.06 1.0 0.04
Monophasic disease course at last follow-up 14/51 (27) 13/38 (34) 18/67 (27) 0.6 0.5 1.0
Median clinical follow-up duration, mo 30 (4–143) 19 (4–121) 31 (6–201) 0.3 0.02 0.3
Abbreviations: AQP4-IgG-NMOSD = aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder; AZA = azathioprine; DMF = dimethyl
fumarate; EDSS = Expanded Disability Status Scale; FGD = fingolimod; GA = glatiramer acetate; IFN = Interferon; IVIg = IV immunoglobulin; MMF = myco-
phenolatemofetil; MOGAD =myelin oligodendrocyte glycoprotein–immunoglobulin G–associated disorder; MS =multiple sclerosis; NTZ = natalizumab; OCB
= oligoclonal bands; PLEX = plasma exchange; TER = teriflunomide.
Results are presented as number (%) unless specified otherwise.
a In 54 patients, the index attack was preceded by other disease-related CNS manifestations including optic neuritis, brain/brainstem manifestations (in
patients with myelitis index attack), or myelitis (in patients with brain index attack).
b Rituximab or ocrelizumab.
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index lesion always coincided with normalization of the spinal
cord MRI at follow-up.
MRI Normalization of T2 Signal Abnormalities
A complete resolution of all the specific T2 abnormalities at
MRI follow-up was more common with MOGAD for both
brain (MOGAD, 39%; AQP4-IgG-NMOSD, 10%; MS, 5%)
and spinal cord (MOGAD, 79%; AQP4-IgG-NMOSD, 0%;
MS, 0%) attacks (Tables 2 and 3). By reviewing all available
follow-up MRIs (including those obtained before 6 months),
the median (range) time in months from acute to first avail-
able normal brain MRI in those in whom T2 lesions resolved
were as follows: MOGAD, 19 (1–96); AQP4-IgG-NMOSD,
26 (18–95); MS, 11 (10–13). In patients with MOGAD with
a myelitis attack, the median (range) time to first normal
follow-up MRI was 9 months (1–96).
Determinants of Lesion Resolution in MOGAD
By using logistic regression to predict T2 lesion resolution in
patients with MOGAD, no significant association was found
with time interval between acute and follow-upMRI, sex, acute
lesion area, abnormal gadolinium enhancement on acute MRI,
interval disease relapses in other CNS regions, cervical vs
thoracic spinal cord location (in patients with myelitis only),
MOGAD phenotype (acute disseminated encephalomyelitis/
multifocal CNS involvement vs other), monophasic vs re-
lapsing course of the disease, administration of acute treatment
and its type (monotherapy vs multiple agents), or com-
mencement of long-term immunosuppressive therapy and its
types (anti-CD20 vs oral immunosuppressants [azathioprine or
mycophenolate mofetil] vs MS disease-modifying agents).
Moreover, there was no difference between pediatric (age <18
years) and adult patients with MOGAD in the frequency of
brain index lesion resolution (7/11 [64%] vs 6/7 [86%]; p =
0.6), brain MRI normalization (4/11 [36%] vs 3/7 [43%]; p =
1.0), and spinal cord MRI normalization (5/8 [63%] vs 17/20
[85%]; p = 0.3). Lastly, for those in whom repeated MOG-IgG
testing was available, the frequency of lesion resolution did not
differ significantly for transient (i.e., testing negative at least 6
months after the initial MOG-IgG positivity) vs persistent (≥6
months) antibody positivity and brain (3/4 [75%] vs 8/10
[80%]; p = 1.0) or myelitis (3/6 [50%] vs 10/12 [83%]; p =
0.27) attacks, respectively.
Clinical Characteristics of Patients With MRI
Normalization
In the MOGAD group, the median EDSS at last clinical
follow-up was similar in those who showed a normal MRI










Brain attacks, n 21 18 42 — — —
Number of brain MRI T2 lesions >15 on attack MRI 9/21 (43) 10/18 (56) 20/42 (48) 0.5 0.8 0.8
Infratentorial T2 lesions on attack MRI 19/21 (90) 14/18 (78) 36/42 (86) 0.4 0.5 0.7
Axial area of the index T2 lesion in mm2 on attack
MRI
167 (14–635) 213 (66–873) 58 (8–754) 0.1 <0.001 0.01
Gadolinium enhancement on attack MRI 13/20 (65) 8/18 (44) 29/39 (74) 0.3 0.03 0.4
Resolution of the index T2 lesion at follow-up 3/21 (14) 13/18 (72) 7/42 (17) <0.001 <0.001 1.0
Normal brain MRI at follow-up 2/21 (10) 7/18 (39) 2/42 (5) 0.05 0.002 0.6
Residual axial area of the index T2 lesion in mm2 on
follow-up MRI
26 (0–247) 0 (0–114) 13 (0–248) 0.002 0.01 0.1
Delta axial area reduction of the index T2 lesion in
mm2 from acute MRIa
104 (0.7–597) 213 (55–873) 36 (0–506) 0.02 <0.001 0.01
% Axial area reduction of the index T2 lesion from
acute MRIb
78 (4–100) 100 (63–100) 75 (0–100) <0.001 <0.001 0.8
Persistent enhancement on follow-up MRI 0/13 (0) 0/8 (0) 0/29 (0) — — —
Residual T1 hypointensity for the index lesion 9/21 (43) 0/18 (0) 20/42 (48) 0.002 <0.001 0.8
Any residual brain T1 hypointensity at follow-upMRI 12/21 (57) 3/18 (17) 35/42 (83) 0.02 <0.001 0.03
Time interval from acute to follow up MRI, mo 43 (6–143) 21 (10–109) 37 (7–192) 0.9 0.3 0.5
Abbreviations AQP4-IgG NMOSD = aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder; MOGAD = myelin oligodendrocyte
glycoprotein–immunoglobulin G–associated disorder; MS = multiple sclerosis.
Results are presented as median (range) or n (%).
a Delta area reductions were calculated for each patient as (acute area – follow-up area).
b % Area reductions were calculated as (acute area – follow-up area)/acute area.
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(brain, EDSS 1 [range, 0–2]; myelitis, EDSS 1 [0–6.5]) vs
those who did not (brain, EDSS 1 [range, 0–3.5]; myelitis,
EDSS 0.5 [range, 0–7]) (p ≥ 0.6 for all comparisons). The
frequencies of interval relapses were similar. Three patients
with isolated MOGAD myelitis (and no other disease re-
lapses) had residual symptoms of spinal cord dysfunction at
the time of the normal follow-up MRI, including subjective
sensory disturbances (n = 3: itching, burning, tingling),
bladder dysfunction (n = 2: increased urinary frequency,
urinary hesitancy), and mild gait instability (n = 1). Also, one
patient with clinically isolated syndrome of brainstem de-
myelination resulting in acute bilateral internuclear
ophthalmoplegia had residual intermittent diplopia and gaze-
evoked nystagmus at last follow-up despite brain MRI nor-
malization. All other patients with normalization of the MRI
at follow-up either had no residual disability at last follow-up
or a residual clinical deficit explained by other attacks.
Reductions in Size of Index T2 Lesions
In patients with brain attacks, the median axial area reduction
for the index lesions was higher in MOGAD (213 mm2 [range,
55–873]) compared to AQP4-IgG-NMOSD (104 mm2
[range, 0.7–597]) and MS (36 mm2 [range, 0–506]) (p <
0.001), although no significant difference was observed











Spinal cord attacks, n 34 28 29 — — —
Number of spinal cord T2 lesions on attack MRI 1 (1–5) 1 (1–4) 2 (1–6) 0.046 0.2 0.001
Sagittal length of the index T2 lesion in VBS on
attack MRI
6.25 (1–19) 4.5 (0.5–19) 1 (0.5–2) 0.2 <0.001 <0.001
Sagittal area of the index T2 lesion inmm2 on attack
MRI
437 (46–2,120) 279 (17–888) 64 (19–229) 0.05 <0.001 <0.001
Axial area of the index T2 lesion in mm2 on attack
MRI
39 (9–118) 45 (4–100) 21 (9–62) 0.8 0.005 <0.001
Gadolinium enhancement on attack MRI 32/34 (94) 15/28 (54) 25/28 (89) <0.001 0.01 0.7
Resolution of the index T2 lesion on follow-up MRI 0/34 (0) 22/28 (79) 0/29 (0) <0.001 <0.001 —
Normal spinal cord MRI at follow-up 0/34 (0) 22/28 (79) 0/29 (0) <0.001 <0.001 —
Residual sagittal length of the index T2 lesion in VBS
on follow-up MRI
2.5 (0–7) 0 (0–7) 0.5 (0–2) <0.001 <0.001 <0.001
Residual sagittal area of the index T2 lesion in mm2
on follow-up MRI
87 (0–513) 0 (0–237) 34 (5–229) <0.001 0.001 <0.001
Delta sagittal area reduction of the index T2 lesion
in mm2 from acute MRIa
309 (0–1885) 262 (0–888) 23 (0–152) 0.4 <0.001 <0.001
%Sagittal area reductionof the index T2 lesion from
acute MRIb
74 (0–100) 100 (0–100) 39 (0–94) <0.001 <0.001 <0.001
Residual axial area of the index T2 lesion in mm2 on
follow-up MRI
9 (0–30) 0 (0–60) 10 (0–32) <0.001 <0.001 0.6
Delta axial area reduction of the index T2 lesion in
mm2 from acute MRIa
23 (1–118) 34 (4–100) 10 (0–48) 0.3 <0.001 <0.001
% Axial area reduction of the index T2 lesion from
acute MRIb
71 (0–100) 100 (33–100) 53 (0–100) <0.001 <0.001 0.001
Persistent enhancement on follow-up MRI 0/32 (0) 0/15 (0) 0/25 (0) — — —
Residual T1 hypointensity for the index lesion 3/34 (9) 0/28 (0) 1/29 (3) 0.2 1.0 0.6
Any residual spinal cord T1 hypointensity at follow-
up MRI
3/34 (9) 0/28 (0) 1/29 (3) 0.2 1.0 0.6
Time interval from acute to follow-up MRI, mo 31 (6–138) 15 (7–104) 26 (6–201) 0.1 0.04 0.6
Abbreviations AQP4-IgG NMOSD = aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder; MOGAD = myelin oligodendrocyte
glycoprotein–immunoglobulin G–associated disorder; MS = multiple sclerosis; VBS = vertebral body segments.
Results are presented as median (range) or n (%).
a Delta area reductions were calculated for each patient as (acute area – follow-up area).
b % Area reductions were calculated as (acute area – follow-up area)/acute area.
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between patients with AQP4-IgG-NMOSD and MS in the
median relative % reduction from acute MRI (Table 2). In the
spinal cord, the median index lesion area reduction was similar
in MOGAD and AQP4-IgG-NMOSD on both sagittal (262
[range, 0–888] vs 309 [range, 0–1885] mm2; p = 0.4) and axial
(34 [range, 4–100] vs 23 [range, 1–118]mm2; p = 0.3) images,
although the median relative % reduction in size compared to
the acute MRI was higher in the MOGAD group (Table 3).
In the MS group, both the median axial area reduction in mm2
and the relative%T2 lesion reduction from the acuteMRIwere
lower compared to the MOGAD and AQP4-IgG-NMOSD
groups (p < 0.001 for all comparisons; Table 3).
Other MRI Measures
None of those with enhancing lesions acutely showed per-
sistent enhancement at follow-up in any of the 3 groups
(Tables 2 and 3). Residual T1 hypointensity of the index brain
lesion and of all brain lesions was lowest with MOGAD vs
AQP4-IgG-NMOSD and MS (Table 2) but was very in-
frequently detected in the spine across all groups (Table 3).
Discussion
We identified clear differences in T2 lesion evolution between
MOGAD, AQP4-IgG-NMOSD, andMS that may help define
their different disease courses, inform the diagnosis, and help
plan future clinical trials. Demyelinating T2 lesions inMOGAD
tend to resolve completely at follow-up despite their large size
acutely and initial accompanying severe clinical impairment,
which is in line with the favorable long-term outcome reported
in most patients.12 T2 lesions associated with AQP4-IgG are
similar to those observed in MOGAD in terms of accompa-
nying clinical severity and size but rarely resolve completely and
despite a large reduction in size (generally 60%–80% from the
acute MRI) small regions of residual T2 hyperintensity are
usually evident. This presumed scarring onMRI, along with the
Figure 2 Brain MRI T2 Lesion Evolution in Aquaporin 4–Immunoglobulin G–Positive Neuromyelitis Optica Spectrum Dis-
order (AQP4-IgG-NMOSD), Myelin Oligodendrocyte Glycoprotein–Immunoglobulin G–Associated Disorder
(MOGAD), and Multiple Sclerosis (MS)
Axial fluid-attenuated inversion recovery infratentorial (A, C, E) and supratentorial (B, D, F) brainMRI are shown. In patientswith AQP4-IgG-NMOSD (A, B), large
acute lesions (A.a, B.a) commonly show a prominent reduction of their initial size but rarely resolve completely, typically leaving tiny residual abnormalities
(A.b, B.b; red circles). In patients with MOGAD (C, D), most large acute T2-hyperintense lesions (C.a, D.a) resolve to undetectable (C.b) at follow-up MRI,
although some acute T2 lesions can leave some (often nonspecific) small foci of T2 hyperintensity (D.b; red circle). In patients with MS (E, F), acute T2-
hyperintense lesions are relatively smaller (E.a, F.a) and typically showmoderate reduction in size at follow-up, while remaining clearly detectable (E.b, F.b; red
circles).
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greater associated spinal cord atrophy compared to MOGAD
described in prior studies,23 are consistent with the incomplete
recovery and stepwise attack-related disability accumulation
reported in AQP4-IgG-NMOSD.24 MS lesions are character-
ized by smaller size and less severe attacks acutely but only
showmoderate reduction in size (generally 30%–70% from the
acute MRI) and rarely resolve completely despite resolution of
clinical features. We speculate that persistence of these T2
lesions, particularly larger lesions in critical locations, over
time may represent a nidus for secondary disability pro-
gression and the tendency of some MS lesions to remain
chronically active between relapses (smoldering MS lesions)
could support this hypothesis.25,26 Moreover, reports of
progressive disability attributable to a single persistent large
T2 lesion in an eloquent location (such as the spinal cord
lateral columns) that becomes focally atrophic over time is
also consistent with this proposition.27-29
While the persistence of MS lesions over time is well-
recognized, lesion evolution in MOGAD and AQP4-IgG-
NMOSD is much less well studied and mostly analyzed in
subsets of prior studies. In a cohort of children with de-
myelinating CNS disorders, normalization of spinal cord
MRI after the acute phase was observed in 6/8 (75%)
MOGAD and 0/4 (0%) AQP4-IgG-NMOSD cases with
longitudinally extensive transverse myelitis.30 Complete
resolution of brain MRI abnormalities was also reported in
25/42 (60%) children with MOGAD after a median of 4
years, but only 20/109 (18%) seronegative patients with
pediatric CNS demyelination (with approximately half of the
patients having an MS phenotype, none of whom showed
lesion resolution).31 We have previously reported patients
with MOGAD with long follow-up (median of 14 years) and
highly relapsing course with a normal follow-up MRI of the
brain and spinal cord observed in 18/25 (72%) and 6/6
(100%) patients, respectively.12 Also, a recent series of pa-
tients with MOGAD with brainstem or cerebellar attacks
from our group showed lesion resolution at ≥6 months ob-
served in 6/9 (67%) patients.21 Accepting differences in
study design and follow-up durations, these numbers are in
Figure 3 Spinal Cord MRI Lesion Evolution in Aquaporin 4–Immunoglobulin G–Positive Neuromyelitis Optica Spectrum
Disorder (AQP4-IgG-NMOSD), Myelin Oligodendrocyte Glycoprotein–Immunoglobulin G–Associated Disorder
(MOGAD), and Multiple Sclerosis (MS)
Sagittal (A.a, B.a, C.a, D.a, E.a, F.a) and axial (A.b, B.b, C.b, D.b, E.b, F.b) thoracic spinal cord T2-weighted images are shown. In patients with myelitis, T2-
hyperintense lesions associated with AQP4-IgG-NMOSD, longitudinally extensive lesions with swelling of the spinal cord (A.a) and holocord involvement
acutely (A.b [T7 vertebral body level]), frequently show a dramatic reduction in size at follow-up MRI but remain detectable, often accompanied by focal
lesional spinal cord atrophy (B.a, B.b [T7 vertebral body level]). In patients with MOGAD myelitis, the acute ventral-predominant long T2 lesion extending to
the conus (C.a) is gray matter restricted axially (C.b [T3 vertebral body level]) and resolved completely at follow-up MRI (D.a, D.b [T3 vertebral body level]). In
patients with MS, the typically short acute myelitis T2-hyperintense lesion (E.a, E.b [T6-T7 vertebral body level]) often only has modest reduction in size at
follow-upMRI (F.a, F.b [T6-T7 vertebral body level]), at which time it can be better appreciated to involve the periphery (right lateral columns) of the spinal cord
on axial images (F.b [T6-T7 vertebral body level]).
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line with our findings and suggest MRI normalization in
MOGAD may occur even after multiple attacks. A prior
study specifically analyzed brain lesion evolution on MRI in
63 patients with NMOSD (95% with AQP4-IgG), for a total
of 211 acute brain lesions, and found complete resolution in
24% of these.17 The lower frequency of lesion resolution in
our study could be related to the greater predominance of
infratentorial lesions in our study as differences in lesion
location can affect the degree of tissue injury but differences
in inclusion criteria, MRI scanners, or the role of chance are
other possible explanations.
Our findings have relevance for current clinical practice for
helping select individuals at a higher risk of MOGAD. Reso-
lution of most or all lesions and marked reduction in lesion size
in a patient with CNS demyelinating disease and prior attacks
will help select those at higher risk for MOGAD and may avoid
testing in low probability situations in which the risk of false
positivity increases. Given that MOG-IgG has only become
available recently, there are large numbers of patients with
MOGAD with serial imaging available who may have not been
tested yet forMOG-IgG and for whom our findings are directly
applicable. Similarly, complete or near complete T2 lesion
resolution can be used, in addition to other measures, when a
positive MOG-IgG test is encountered to help distinguish true
vs false-positive results, particularly when antibody titer is low
and the risk of false positivity is higher (up to a quarter of
positive results may be false-positives when the test is per-
formed indiscriminately in a real-life clinical setting).32
Awareness of the variability in CNS demyelinating lesion
evolution across these disorders over time is important for
Figure 4 Graphical Comparison of MRI Evolution of T2 Lesions in the 3 Disease Groups
(A) Bar graphs show the different frequency of the analyzed measures in patients with aquaporin 4–immunoglobulin G–positive neuromyelitis optica
spectrum disorder (AQP4-IgG-NMOSD) (dark blue bars), myelin oligodendrocyte glycoprotein–immunoglobulin G–associated disorder (MOGAD) (light blue
bars), and multiple sclerosis (MS) (green bars) in the brain and spinal cord. Although the largest reduction in size was observed in AQP4-IgG-NMOSD and
MOGAD associated lesions, only the latter show complete resolution of MRI abnormalities at follow-up in the majority of cases. On the contrary, MS lesions
showed the smallest reduction in size at follow-up and, similarly to AQP4-IgG-NMOSD lesions, were unlikely to resolve completely. Statistically significant
differences between 2 groups are indicated by the asterisks on top of the bars (***). (B) Themedian largest area for brain and spinal cord lesions axially, and
sagittally for the spinal cord only, acutely and at follow-up MRI for the 3 groups. The exact p values for different comparisons are shown in tables 2 and 3.
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optimal selection of outcome measures in clinical trials. De-
velopment of new or enlarging T2 lesions on brain MRI is
often used as a primary outcome measure in MS as it allows
assessment of interattack disease activity, but relies on the
tendency of MS lesions to persist over time. A similar ap-
proach for MOGAD would be more problematic given the
high frequency of lesion resolution as one or more transient
T2 lesions could appear and disappear between interval MRI
scans. This could also contribute to the low incidence of new
asymptomatic T2 lesions reported in children with MOGAD
in a prior study.33 Notably, lesion resolution in this study was
not associated with less disability compared to patients with
MOGAD in whom lesions persisted, suggesting that T2
abnormalities alone do not properly reflect functional im-
pairment in MOGAD.34 A similar clinical–MRI discrepancy
in MOGAD is sometimes seen during severe attacks ac-
companied by normal MRI.35 Finally, no patients had per-
sistent gadolinium enhancement of lesions after 6 months
and its presence should be a red flag for alternative non-
demyelinating etiologies as illustrated by a prior study that
showed it favored sarcoid myelopathy over AQP4-IgG-
NMOSD myelitis.36
The mechanisms that underlie the tendency of MOGAD lesions
to resolve completely are not fully understood. The timing of
lesion resolution in patients with MOGAD varied from days to
many months and the lack of predefined intervals of MRI scans
limits its assessment as it is difficult to determine at what time
point between 2 MRIs the lesions may have resolved. The fre-
quency of a normal MRI without residual T2 lesions was greater
in the spine than brain and likely reflects themuch higher number
of brain than spine lesions, with each attack allowing greater
number of opportunities to leave a residual scar (e.g., Figure 2D).
It is also notable that lesion resolutionwas similar before and after
18 years of age. Together, these observations suggest that lesion
resolution is not just a time or age-dependent process but other
lesion- or patient-specific factors are likely involved. De-
myelinating lesions in AQP4-IgG-NMOSD and MOGAD
showed a similarly large reduction in size, some of which may
reflect greater reduction in edema from large edematous T2
lesions (particularly in the spinal cord) when compared to MS.
However, lesion resolution was common only with MOGAD.
Greater remyelination capacity, less neuronal loss, or a pre-
dominant functional vs structural damage inMOGAD compared
to AQP4-IgG-NMOSD and MS might account for this differ-
ence. Occasionally, severe edema with AQP4-IgG-NMOSD
myelitis lesions in a confined spinal compartment could lead to
secondary ischemia and play a role in lesion persistence, although
lesion persistence was similarly observed in brain lesions associ-
ated with AQP4-IgG and other factors such as complement
mediated tissue destruction are likely to contribute to residual
scarring.37 This is also in line with the rarer occurrence of residual
brain parenchymal T1 hypointensity after MOGAD, which
supports better tissue healing and potentially less destructive le-
sions leading to more favorable outcomes in MOGAD. Obtain-
ing further insight on lesion evolution from pathologic studies is
limited as biopsy/autopsy assessments are generally from acute
severe attacks with only scarce available data on the pathologic
characteristics of lesions between attacks.38-40
This study is limited by its retrospective nature and lack of
standardized MRI assessment of CNS lesions at a regular time
interval on the sameMRI scanner. Such studies are needed, but
they may be difficult to perform. Acquiring attack MRIs, which
may be undertaken at various locations (e.g., in the hospital
setting), and obtaining research MRIs in the acute setting can
be complicated with ethical issues if general anesthesia is re-
quired (e.g., encephalopathic patients). Moreover, given the
rarity of MOGAD and AQP4-IgG-NMOSD and requirement
of no interval attacks involving that same region, prospective
MRI studies with sufficient power will be costly, likely require
multiple centers, and could take a long time, as illustrated by
this retrospective single-center study encompassing >15 years.
Thus, this study provides valuable data while such prospective
studies are awaited. The use of advanced MRI sequences or
higher magnetic field scans could improve the detection of
residual abnormalities not appreciable on conventional se-
quences but a benefit of our study with conventionalMRI is the
direct reproducibility to current clinical practice. Some tech-
nical aspects might bias lesion resolution assessment (e.g., we
compared acute and follow-up images on different MRI scans
and the variation in axial/sagittal cuts may miss small residual
lesions), but the magnitude of the differences we found among
the 3 groups could not be explained by these technical issues
(Figures 1–4). Moreover, although comparing different MRI
examinations over time introduces variability in imaging
equipment, software, patient positioning, series techniques, and
slice selection, these would be expected to be random variables
without systematic bias. Patients received many different
treatments after the initial attack and had variable follow-up
durations that might have contributed to the observed differ-
ences in the 3 groups. However, both acute and maintenance
therapy were very similar in patients with AQP4-IgG-NMOSD
and MOGAD (Table 1), plus patients with MOGAD had
shorter time interval between acute and follow-upMRI (Tables
2 and 3), and thus timing did not explain their higher frequency
of lesion resolution. The proportion of patients with MS
treated with anti-CD20 drugs was relatively low in our study
but these drugs might increase the frequency of MS lesion
resolution. Future studies will better clarify the specific effect of
different acute and maintenance immunosuppressive agents
(e.g., anti-CD20 vs oral immunosuppressants [azathioprine or
mycophenolate mofetil] vs MS disease-modifying agents) on
MRI lesion evolution. Chronic T2 lesions preceding the initial
acute MRI could influence lesion resolution but our study
design requiring the first ever clinical attack attributable to the
region of interest reduced the risk of inclusion of such lesions.
Agemay affect the capacity for lesion resolution but this did not
differ between children and adults in this study, although fur-
ther studies with larger numbers of pediatric patients are
needed. Lastly, evolution of optic nerve lesions onMRI was not
analyzed in this study due to the limited availability of dedicated
orbital sequences and technical issues can limit the reliability of
T2 lesion detection in the optic nerves.
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This comparative study on the temporal evolution of MRI
lesions associated with MOGAD, AQP4-IgG-NMOSD, and
MS has relevance for clinical practice and our understanding
of the pathogenesis of these disorders.
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